News

Aileron Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update

Aileron Therapeutics today reported business highlights and financial results for the second quarter ended June 30, 2020.

Read More
Aileron Therapeutics Announces Completion of Enrollment in Dose Optimization Expansion Cohort of Proof-of-Concept Phase 1b Study of ALRN-6924

Aileron Therapeutics announced today that it has completed enrollment in the dose optimization expansion cohort of its ongoing open-label Phase 1b clinical study of ALRN-6924.

Read More
Aileron Therapeutics to Present at Two Upcoming Investor Conferences in August

Aileron Therapeutics today announced that Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences this month.

Read More
Aileron Therapeutics Initiates Enrollment in Schedule Optimization Part of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent in Small Cell Lung Cancer (SCLC) Patients Being Treated with Topotecan

The schedule optimization part of the trial is intended to determine whether ALRN-6924 given six hours before topotecan further enhances the protective effect of ALRN-6924 against severe hematological adverse events observed when ALRN-6924 was given 24 hours before topotecan in the dose optimization part of the trial, as reported by Aileron earlier this month.

Read More
Aileron Therapeutics Announces Closing of Public Offering of Common Stock and Exercise of Option to Purchase Additional Shares

Aileron Therapeutics announced today the closing of its underwritten public offering of its common stock, including the exercise by the underwriter of their option to purchase an additional 1,071,149 shares at the public offering price of $1.10 per share. The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by Aileron to 10,162,059 shares and increased the amount of gross proceeds to $11.2 million, before deducting underwriting discounts and commissions and offering expenses payable by Aileron.

Read More
Aileron Therapeutics Announces Pricing of Public Offering of Common Stock

Aileron Therapeutics announced today the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a public offering price of $1.10 per share, for aggregate gross proceeds of $10.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Aileron. In addition, Aileron has granted the underwriter a 30-day option to purchase up to 1,363,636 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares are being sold by Aileron. The offering is expected to close on June 8, 2020, subject to the satisfaction of customary closing conditions.

Read More
Aileron Therapeutics Announces Positive Interim Results from Phase 1b/2 Clinical Trial of ALRN-6924 for the Prevention of Topotecan-induced Toxicities During Treatment for Small Cell Lung Cancer

Aileron Therapeutics announced today positive interim data from the open-label Phase 1b dose optimization part of its ongoing Phase 1b/2 clinical trial. In this trial, ALRN-6924 is being evaluated as an agent to protect patients against chemotherapy-induced toxicity, a concept known as chemoprotection (or myelopreservation). Patients in the trial have advanced, p53-mutated small cell lung cancer (SCLC) and are being treated with second-line topotecan following administration of ALRN-6924. A protective effect against severe chemotherapy-induced anemia and thrombocytopenia was observed in 17 evaluable patients across all dose levels as compared to historical controls. In addition, patients treated with 0.3 mg/kg ALRN-6924 met the protocol-defined criteria for reduction of NCI CTC Grade 3/4 neutropenia to ≤50% in the first treatment cycle.

Read More
Aileron Therapeutics Announces Initiation of Expansion Cohort and First Patient Enrolled into Expansion Cohort of Phase 1b/2 Study of ALRN-6924 as a Chemoprotection Agent

Aileron Therapeutics announced today the expansion of one of the dose levels in the dose optimization part of its Phase 1b/2 clinical trial evaluating ALRN-6924 as an agent to protect patients with small cell lung cancer (SCLC) against chemotherapy-induced toxicity, a concept known as chemoprotection (or myelopreservation). The first patient has been enrolled into the expansion cohort, which was triggered by results from the ongoing trial that met protocol-specified criteria for expansion.

Read More
Aileron Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

Aileron Therapeutics (NASDAQ:ALRN) reported business highlights and financial results for the first quarter ended March 31, 2020, including completion of enrollment in the dose optimization part of the ongoing Phase 1b/2 clinical trial of ALRN-6924 as a chemoprotection agent in cancer patients, and plans to report interim results from the dose optimization part of the Phase 1b/2 trial 2nd Quarter of 2020.

Read More
Aileron Therapeutics Announces Plans to Release Interim Results from its Phase 1b/2 Myelopreservation Study in Mid-2020

Aileron Therapeutics (NASDAQ:ALRN) today announced plans to report interim results from their Phase 1b/2 clinical trial of ALRN-6924 in small cell lung cancer (SCLC). In this trial, ALRN-6924 is being evaluated as an agent to protect cancer patients against chemotherapy-induced toxicity, a concept known as myelopreservation or chemoprotection.

Read More